Clinical Trial Update: A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of remibrutinib in adults with chronic spontaneous urticaria inadequately controlled by H1-antihistamines has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• Remibrutinib (remibrutinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Spontaneous Urticaria | Phase 3 | Status: COMPLETED | Results posted: 2024-11-01